A phase 2 Open-label Study of MEDI-551 and bendamustine vs Rituximab and Bendamustine in Adults with Relapsed or Refractory CLL
In this study, two different doses of the experimental study drug, MEDI-551, will be examined in combination with bendamustine to see how they compare to rituximab in combination with bendamustine in terms of slowing down the growth of CLL or bringing CLL into remission. Participants in this study have progressive chronic lymphocytic leukemia (CLL) that has not responded to or stopped responding to treatment with standard anticancer medicines. Although the combination of bendamustine and rituximab has not been approved by the FDA, this combination has been used clinically to treat patients whose disease has not responded or has recurred (the cancer has come back). Thus, both drug combinations (MEDI 551 + bendamustine or rituximab + bendamustine) are considered experimental.
Back to Clinical Trials list